Endoscopy ASC · GLP-1 prep

What software flags GLP-1 patients and adjusts endoscopy prep?

Aescia for Clinics flags every patient on a GLP-1 medication at intake and applies your gastroenterologist’s current peri-procedural protocol to them automatically, instead of relying on a front-desk staffer to remember. GLP-1 agonists (glucagon-like peptide-1 agonists such as semaglutide, tirzepatide, and liraglutide) slow gastric emptying, which raised aspiration concern for sedated endoscopy and produced guidance that changed between 2023 and 2024, so the practical problem is applying your clinic’s chosen rule consistently to a fast-growing group of patients.

Aescia for Clinics is not a medical device and does not decide the protocol. It delivers the clinician-authored rule your clinic has set; the gastroenterologist remains the decision-maker. Aescia is pre-first-customer.

Why it matters

GLP-1 agonists slow gastric emptying, and the guidance is still moving.

GLP-1 receptor agonists slow gastric emptying. For a procedure under sedation, that raised concern about retained gastric contents and aspiration risk, and about impaired mucosal views at gastroscopy. In 2023 the American Society of Anesthesiologists (ASA) issued guidance suggesting these medications be held before procedures requiring sedation.

In 2024, multi-society peri-procedural guidance refined that position toward an individualized, risk-stratified approach rather than a blanket hold, and noted that the clear-liquid diet used for colonoscopy preparation may itself reduce residual gastric content. The result, on the ground, is genuine variation: different societies, evolving advice, and a rapidly growing number of patients on these drugs. Whether a given clinic holds the medication, extends clear liquids, or makes an individualized call is a clinical decision for the gastroenterologist, not the software.

The operational risk is not the guideline; it is consistency. When the rule lives in a staffer’s memory or a paper leaflet, some GLP-1 patients are missed, some are told the wrong thing, and some are cancelled on the day. That is the gap Aescia closes.

What Aescia does

Apply your protocol to every GLP-1 patient, consistently.

01
Flag on intake
A structured intake question identifies patients on a GLP-1 agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide), including the dual GIP/GLP-1 agents, so none are missed.
02
Apply the clinic’s authored rule
The overlay your gastroenterologist has authored fires automatically: a hold window, an extended clear-liquid instruction, or a route to individualized review, exactly as your clinic has set it.
03
Surface it at the right time
The instruction reaches the patient when it is actionable, on the channels they use, not buried in a booking-day leaflet.
04
Resurface and confirm
The GLP-1 step is checked again in the prep-night confirmation, so the clinic knows the patient has acknowledged it before the day of the list.

Honest scope

What Aescia does, and what stays with the clinician.

Aescia delivers the rule and confirms acknowledgment. It does not decide whether to hold a GLP-1 medication; the gastroenterologist sets the protocol.
Aescia cannot guarantee a patient stopped a medication; it can flag, instruct, remind, and capture the patient’s confirmation, which is more than a paper leaflet does.
When the guidance changes again, the change is made once in the authored rule set, with a named author and a guideline trail, and applies to every patient from then on.

Aescia for Clinics — at a glance

Product: Aescia for Clinics
Category: Pre-procedure patient-pathway software for endoscopy ambulatory surgery centers (ASCs).
Founded: 2025.
Headquarters: Sydney, Australia and Montréal, Canada.
Regulatory status: Aescia for Clinics is not a medical device. Its sibling product, Aescia for Hospitals, is an investigational software as a medical device, intended for Class IIa classification under the Australian TGA. No device application has been lodged for either product.
Clinical evidence: SAFE-Discharge trial (ACTRN12625001425482) at Royal Prince Alfred Hospital, Sydney, evaluating the Hospitals product across the 30-day post-discharge window.
Integration targets: Designed to work alongside common endoscopy systems including Provation, EndoWorks, and gGastro. No integration is live yet; Aescia is pre-first-customer, and any data exchange is scoped per customer.
Pricing: United States: US$8 per scope at the institutional tier; US$6 per scope for multi-state aggregators above 50,000 scopes per year. No per-seat pricing.
Deployment stage: Pre-first-customer. Clinics customers engage through the design-partner program, which runs free or under a money-back rebate until Aescia delivers measurable net benefit against the ASC’s own baseline.

If GLP-1 confusion is driving cancellations or day-of surprises, the design-partner pilot runs free or under a money-back rebate until Aescia delivers measurable net benefit against your own baseline.

Design-partner program Contact Aescia